晚期转移性黑色素瘤患者生存:MAP激酶通路抑制与免疫检查点抑制的影响—2019更新
该探索性分析数字化了26项临床试验的84条Kaplan-Meier生存曲线,按治疗策略和线数分组加权平均生成PFS和OS曲线。一线治疗中,3年OS比例分别为BRAF+MEK抑制41.3%、PD-1抑制49.9%、CTLA-4+PD-1抑制58.4%;前12个月BRAF+MEK抑制占优,之后PD-1单药或联合CTLA-4占优。二线及以上,BRAF+MEK抑制在前三年优于抗PD-1单药,3年OS比例分别为42.4%和40.1%。
要点
- 一线治疗3年OS比例:BRAF+MEK抑制41.3%,PD-1抑制49.9%,CTLA-4+PD-1抑制58.4%。
- 一线治疗前12个月BRAF+MEK抑制的PFS和OS曲线优于免疫检查点抑制,之后免疫检查点抑制占优。
- 二线及以上治疗前三年BRAF+MEK抑制优于抗PD-1单药,3年OS比例分别为42.4%和40.1%。
核心结论
- 按治疗策略分组的生存曲线高度一致,一线治疗一致性高于后线治疗。
- 一线治疗前12个月BRAF+MEK抑制的PFS和OS曲线优于免疫检查点抑制,之后PD-1单药或联合CTLA-4占优。
- 二线及以上治疗中,BRAF+MEK抑制在前三年的PFS和OS曲线优于抗PD-1单药。
- 上述结果需头对头随机对照临床试验确认。
研究设计与样本
- 探索性分析,数字化26项临床试验的84条Kaplan-Meier生存曲线。
- 按治疗策略和治疗线数分组,加权平均生成PFS和OS平均生存曲线。
主要发现
- 一线治疗平均3年OS比例:BRAF+MEK抑制41.3%,PD-1抑制49.9%,CTLA-4+PD-1抑制58.4%。
- 二线及以上治疗平均3年OS比例:BRAF+MEK抑制42.4%,PD-1抑制40.1%。
- 按治疗策略分组的生存曲线显示高度一致性,一线治疗一致性高于后线治疗。
临床怎么用
- 一线治疗决策可参考前12个月BRAF+MEK抑制的PFS和OS优势及之后免疫检查点抑制的长期生存优势。
- 二线及以上治疗中,BRAF+MEK抑制在前三年的PFS和OS曲线优于抗PD-1单药。
局限性
- 为探索性分析,非头对头比较,结果需随机对照临床试验确认。
- 生存曲线来自数字化提取和加权平均,非个体患者数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent therapeutic strategies, particularly MAP kinase pathway inhibitors (BRAF, MEK) and immune checkpoint blockers (CTLA-4, PD-1), have been put on the test for their differential impact on long-term survival of metastatic melanoma patients. Various agents, dose regimens and combinations have been tested against each other vigorously within these two therapy groups. However, results from prospective head-to-head comparative trials comparing both strategies against each other are still lacking. METHODS: We performed an exploratory analysis of survival data from selected clinical trials representative for these two treatment strategies in advanced metastatic melanoma. 84 Kaplan-Meier survival curves from 26 trials were digitised and grouped by therapy strategy and treatment line. For each of these groups, mean survival curves were generated for progression-free (PFS) and overall survival (OS) by weighted averaging. RESULTS: Survival curves grouped together by therapy strategy revealed a high concordance, with a larger extent in the first-line setting compared to higher treatment lines. In first-line therapy, the averaged 3-year OS proportions were 41.3% for BRAF plus MEK inhibition, 49.9% for PD-1 inhibition, and 58.4% for CTLA-4 plus PD-1 inhibition. Comparison of the mean PFS and OS curves of kinase inhibition and checkpoint blockade revealed a superiority of combined BRAF plus MEK inhibition within the first 12 months, later changing to a superiority of PD-1 blockers alone or in combination with CTLA-4 blockade. In second-line or higher, BRAF plus MEK inhibition was superior to anti-PD-1 monotherapy throughout the first three years; averaged 3-year OS proportions were 42.4% for BRAF plus MEK inhibition, and 40.1% for PD-1 inhibition. CONCLUSIONS: and relevance: These results need confirmation by head-to-head comparative randomised clinical trials.
引用
- Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. Eur J Cancer. 2020. PMID: 32179447. doi:10.1016/j.ejca.2020.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。